Human papillomavirus infections among women with cervical lesions and cervical cancer in Yueyang, China: a cross-sectional study of 3674 women from 2019 to 2022

被引:0
作者
Min Zeng
Xiaoyun Zhang
LiLi He
Xin Liu
Huawen Liu
Rui Deng
Bo Qiu
Fang Liu
Hang Xiao
Quanlv Li
Wen Li
Chongmei Liu
Yangqing Ge
机构
[1] Yueyang Hospital Affiliated to Hunan Normal University,Department of Gynecology, Yueyang People’s Hospital
[2] Yueyang Central Hospital,Pre
[3] Miluo People’s Hospital,hospital Emergency Center
[4] Pingjiang County Maternal and Child Health Center,Department of Pathology
[5] Yueyang Hospital Affiliated to Hunan Normal University,Department of Pathology
[6] Miluo Maternal and Child Health Center,Department of Clinical Laboratory, Yueyang People’s Hospital
来源
Virology Journal | / 20卷
关键词
Cervical lesions; Cervical cancer; Human papillomavirus; Genotypes;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 253 条
[1]  
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[2]  
Ferlay J(2005)The epidemiology of human papillomavirus infections J Clin Virol 32 S16-24
[3]  
Soerjomataram I(2003)International Agency for Research on Cancer Multicenter Cervical Cancer Study G: Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 518-527
[4]  
Siegel RL(2006)Human papillomavirus and cervical cancer: burden of illness and basis for prevention Am J Manag Care 12 S462-472
[5]  
Torre LA(2010)zur Hausen H, de Villiers EM: classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments Virology 401 70-79
[6]  
Jemal A(2012)Prevention of invasive cervical cancer in the United States: past, present, and future Cancer Epidemiol Biomarkers Prev 21 1402-1408
[7]  
Baseman JG(2013)Human papillomavirus and cervical cancer Lancet 382 889-899
[8]  
Koutsky LA(2016)Prevalence and genotype distribution of hpv infection in China: analysis of 51,345 HPV genotyping results from China's largest CAP certified laboratory J Cancer 7 1037-1043
[9]  
Munoz N(2017)Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial Lancet 390 2143-2159
[10]  
Bosch FX(2017)Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study Lancet Infect Dis 17 1293-1302